Evidence map›Paper›PMID 40487169›Full record

ArticleMaterials today. Bio2025

Integrating gene demethylation and immune modulation: PD-1 nanovesicles as a dual-action therapy for NSCLC.

Heng Zhang, Yuan Liang, Shiyang Deng, Jiang Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Heng ZhangDepartment of Pathology, College of Basic Medical Science, China Medical University, Shenyang, 110122, PR China.
Yuan LiangDepartment of Thoracic Oncology(1), Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, NO.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning, PR China.
Shiyang DengDepartment of Pathology, College of Basic Medical Science, China Medical University, Shenyang, 110122, PR China.
Jiang DuDepartment of Pathology, College of Basic Medical Science, China Medical University, Shenyang, 110122, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) remains a formidable challenge in oncology, underscoring the urgent need for innovative therapeutic strategies. This study explores the potential of PD-1-modified multifunctional nanovesicles (NVs) loaded with 5-azacytidine (5-Aza) for NSCLC treatment. By integrating bioinformatics analyses with

Indexed as

5-AzacytidineEpigenetic therapyImmune activationNon-small cell lung cancer (NSCLC)PD-1-Modified nanovesicles

Identifiers

PMID40487169
PMCPMC12145548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.